Improva Ashoka Shatavari Juice, is designed to be supportive in the management of various gynaecological issue. Improva Ashoka Shatavari Juice is possibly effective as supportive in
Female infertility
- Polycystic ovarian disease (PCOD)
- Pre-menstrual syndrome (PMS)
- Dysmenorrhoea (painful menstruation).
- Dysfunctional uterine bleeding (DUB).
Herbs in Improva Ashoka Shatavari Juice are shown to perform various functions:
- Methi helps reverse insulin resistance. It probably works as an insulin mimetic and increases adeponectin levels. Insulin resistance is implicated in PCOD. Increasing adiponectin levels is a strategy to counter obesity and type II diabetes.
- Ashoka bark is shown to be an uterine tonic possibly due to its oestrogen stimulant activity. It is used traditionally in India for uterine abnormalities, menorrhagia (excessive menstrual bleeding), ammenorhea, painful periods, endometrosis and disorders of the menstrual cycle.
- Shatavari roots are very popular in Ayurveda to treat gynaecological problems. IT has been proposed that Shatavari acts via reducing anti-oxidants and by increasing anti-oxidant capacity of body. In a clinical study on 40 patients that lasted 3 months Shatavari corrected pre-menstrual syndrome (PMS) and dysmenorrhoea (painful menstruation). Many other human studies have shown Shatavari to be useful in dysfunctional uterine bleeding (DUB). Shatavari is possibly useful in female infertility. It is thought to work by stimulating new follicular synthesis, and improving their development.
- Jatamansi, Gokhru are reported to be anti-androgenic and counter the actions of testosterone. These actions are supportive in the management of Polycystic Ovarian disease (PCOD).
- Lodhra is shown to increase FSH and LH hormone levels and is also anti-androgenic. The FSH and LH increasing ability may become useful in the treatment of infertility.
- Various herbs in Improva Ashoka Shatavari Juice are known to provide powerful anti-oxidant and anti-inflammatory actions.
References:
- Pandey, A. K., et al. Biomedicine & Pharmacotherapy, 103, 46–49. doi:10.1016/j.biopha.2018.04.003
- Singh, S. et al. Curr. Sci., 2015, 109, 1790-1801